No significant differences in survival by age, WHO histologic grade, radiotherapy, PD-1 and L1CAM were found, although trends toward improved survival were noted for ependymoma (WHO grade II) versus anaplastic ependymoma (WHO grade III) and low Ki-67 expression versus high expression. The gene discussed is L1CAM; the disease is anaplastic ependymoma.